The low level of DNA methylation in tumors compared to the level of DNA methylation in their normal-tissue counterparts or global DNA hypomethylation was one of the first epigenetic alterations to be found in human cancer 1, 2 . While the contribution of genome hypomethylation in cancer development and progression is explained by several mechanisms: chromosomal instability, loss of imprinting, and reactivation of transposable elements 3, 4 , the molecular causes of genome hypomethylation remain unclear. Indeed, despite the central roles of the DNA methyltransferases (Dnmts) in the establishment and maintenance of the DNA methylation, no clear consensus appears between the reduction of the Dnmts expression and the genome hypomethylation in human cancers 5 . Nevertheless, the cancer-associated genome hypomethylation could be explained by the disruption of interactions existing between Dnmts and the DNA replication and DNA repair proteins because these interactions play a crucial role in the DNA methylation in mammalian cells 6-8 . We here demonstrate that the disruption of the Dnmt1/PCNA and Dnmt1/UHRF1 interactions induce the genome hypomethylation and act as oncogenic factors promoting the tumorigenesis. We also identify the Akt-and/or PKC-mediated phosphorylations of Dnmt1 as both initiators of these disruptions and as a hallmark conferring poor prognosis in glioma patients.
The global DNA methylation status of gliomas was assessed by measuring the number of 5-methylcytosine (5mC) in a collection of 62 surgical resections of gliomas and in 5 nonpathologic brain biopsies (Figure 1a) . ELISA results indicate that the 5mC number decreases when the glioma grade increases (Pearson's correlation test, r=-0.504, p<0.0001). We next complemented this observation by measuring the intra-tumor de novo and maintenance DNA methyltransferase activities (dnMTase and mMTase) in order to determine the contribution of each MTase activities on the global DNA hypomethylation phenotype characterizing the gliomagenesis. Each MTase activity was plotted against the 5mC data and a statistical analysis using the Pearson's correlation test showed a significant correlation between the 5mC and the mMTase activity (r=0.760, p<0.0001), but not between the 5mC and the dnMTase activity (r=0.135, p=0.2761) (Figure 1b) . The Dnmt1 being the predominant maintenance methyltransferase enzyme, we next assessed its expression in glioma biopsies by ELISA. No significant correlation was observed between the Dnmt1 expression and the mMTase activity (Pearson's correlation test, r=-0.202, p=0.1012) (Figure 1c ). Gliomagenesis involving a stepwise accumulation of kinases, we decided to determinate whether the Dnmt1 phosphorylation was a molecular determinant governing the mMTase activity decrease seen above. For this purpose, we estimated the amount of phosphorylated Dnmt1 (pDnmt1) by ELISA using a panel of motif specific antibodies (phospho-Akt substrate-specific (PAS), phospho-(ser)-PKC substrate (PPCS), phospho-(thr)-and phospho-(ser)-CDK substrate (PCS)). pDnmt1-PAS, pDnmt1-PPCS, and pDnmt1-PCS values were plotted against the mMTase activity values. Significant inverse correlations were observed between the pDnmt1-PAS or the pDnmt1-PPCS levels and the mMTase activity (Pearson's correlation test, r=-0.569, p<0.0001 and r=-0.454, p=0.0001), but not between the pDnmt1-PCS and the mMTase activity (Pearson's correlation test, r=-0.045, p=0.7177) (Figures 1d and S1 ).
We next analyzed whether the presence of high quantities of both pDnmt1-PAS and pDnmt1-PPCS could affect the survival time of a subgroup of 53 glioma patients for which we obtained a well-documented medical history (Table S1 ). Based on the pDnmt1-PAS and pDnmt1-PPCS levels found on tumor biopsies, the 53 patients were divided into two groups.
18 patients whose tumors expressed high levels of pDnmt1-PAS and pDnmt1-PPCS simultaneously (equal to or higher than the median value of considered grade) were included in group#1 (in grey on table S1), while 35 patients whose tumors are devoid of this hallmark composed the group#2. Survival curves were estimated by the Kaplan-Meier method and compared with the Cox proportional hazards survival regression test (Figure 1e) . Thus, we observed a significant difference in survival time between patients whose tumors had a high pDnmt1-PAS and pDnmt1-PPCS levels and those whose did not (p=0.001). These results indicate that the high presence of Akt-and PKC-phosphorylated forms of Dnmt1 could be used as an alternative molecular biomarker to predict the disease outcome and/or the prognosis of glioma.
To assess the impact of the Akt-and PKC-phosphorylations of Dnmt1 on the functionality of this enzyme in glioma cells with characteristics similar to the cells present in the tumor mass, we next decided to extend our analyses to primary cultured tumor cells (PCTC) obtained from gliomas because established cell lines diverged from original cells 9 .
ELISA, DMB assay and immunoblots confirmed that PCTCs (as tumors) are characterized by a decrease of 5mC number, a diminution of the mMTase activity, and an increase of the pDnmt1-PAS and/or pDnmt1-PPCS levels all the more important that the tumor grade is elevated (Figure 2a (Figure 2d) . Secondly, our hypothesis was validated by the fact that the amount of Dnmt1/PCNA and Dnmt1/UHRF1 interactions is (supprimé) correlated with the level of Dnmt1 recruited on DNA (Figure 2e) . Thirdly, the fact that Akt and PKC inhibitor treatments restored the Dnmt1/PCNA and Dnmt1/UHRF1 interactions in PCTCs also supported the idea that the Akt-and PKC-induced Dnmt1 phosphorylations negatively regulated the Dnmt1/PCNA and Dnmt1/UHRF1 interactions (Figure 2f) . Thus, all these results demonstrate that the decrease of both Dnmt1/PCNA and Dnmt1/UHRF1 interactions for the benefit of the presence of pDnmt1-PAS and pDnmt1-PPCS is a crucial molecular event generating the decrease of 5mC number seen in tumors via the decrease of mMTase activities. This last point was demonstrated by DMB assay and the hierarchical classification of the mMTase activity effectors namely Dnmt1, pDnmt1-PAS, pDnmt1-PPCS, Dnmt1/PCNA and Dnmt1/UHRF1. Indeed, we noted that the Dnmt1/PCNA and Dnmt1/UHRF1 dimers catalyzed 5-fold more incorporation of methyl group 3 H-radiolabelled than pDnmt1-PAS and pDnmt1-PPCS, and 20-fold more incorporation of methyl group 3 Hradiolabelled than the Dnmt1 (Figure 2g) . In summary, our data identify Akt-and PKCinduced phosphorylations of Dnmt1 as the initiators of the disruption of the Dnmt1/PCNA and Dnmt1/UHRF1 interactions, and the switch "Dnmt1/PCNA and Dnmt1/UHRF1 to pDnmt1-PAS and pDnmt1-PPCS" as the effector of the global DNA hypomethylation phenotype seen in tumors.
We finally wondered whether the global DNA hypomethylation generated disruption of Dnmt1/PCNA and Dnmt1/UHRF1 interactions was an event able to transform the Ntv-a glial cells into glioma. For this purpose, we designed the peGFP-UP plasmid expressing the chimerical protein composed by the GFP reporter protein and by the U and P peptides (defined figure 2c), whose expression inhibited the Dnmt1/PCNA and Dnmt1/UHRF1 interactions but not the Dnmt1/HDAC1 interaction in pull down assay (Figure S3 ). ELISA and immunoprecipitation showed that the Ntv-a/peGFP-UP cells harbored a low level of 5mC via the disruption of the Dnmt1/PCNA and Dnmt1/UHRF1 interactions, compared to the Ntva/peGFP cells (Figure 3a) . The tumorogenicity of the Ntv-a/peGFP-UP and Ntv-a/peGFP cells was assessed by s.c. injection into nude mice and was compared to that of the Ntva/PDGF and Ntv-a/RasAkt cells obtained from the experimental RCAS-system of gliomagenesis 10, 11 . After 2 weeks, we observed macroscopically visible tumors in all 26 injections of Ntv-a/peGFP-UP cells (Figure 3b) . The growth pattern of Ntv-a/peGFP-UPinduced tumors was similar to that of the tumors formed from the injection of Ntv-a/Ras-Akt cells. We also noted that 4/26 Ntv-a/peGFP-UP-induced tumors were invasive (Figure S4) . In culture, the Ntv-a/peGFP-UP cells harbored several hallmarks of cancer cells namely apoptosis evasion, high clonogenicity and high proliferation rate (Figure 3c) . At molecular level, we observed that the Ntv-a/peGFP-UP cells were characterized by the hypomethylation-induced overexpression of BDNF and PDGF-B (Figures 3d and S5) . These findings confirm that the BDNF and PDGF-B genes are epigenetically regulated 12, 13 and suggest that the Ntv-a/peGFP-UP cells acquire the cancer hallmark of self-sufficiency in growth signals 14 . Taken together these results strongly demonstrate that the disruption of the Dnmt1/PCNA and Dnmt1/UHRF1 interactions acts as an oncogenic factor because this event induces the in vivo tumorogenicity, the acquisition of 3 cancer hallmarks 14 (i.e. apoptosis evasion, high proliferation and self-sufficiency in growth signals) and the overexpression of PDGF-B, an oncogene clearly implicated in gliomagenesis 10, 15, 16 (Figure 4) . Thus, while several papers demonstrate that PCNA and/or UHRF1 play a crucial role in the recruitment and/or the anchorage of Dnmt1 on DNA to maintain the DNA methylation pattern of mammalian cells via the capacity of these proteins to bind DNA and hemi-methylated DNA 6, 8, [17] [18] [19] , our work is one of the first to identify the disruption of Dnmt1, PCNA and UHRF1 b, Correlation study between the 5-methylcytosine number (5mC) and the de novo (supprimé) methyltransferase (dnMTase) or the maintenance methyltransferase (mMTase) activities.
Intra-tumor mMTase and dnMTase activities were calculated by using hemi-methylated and unmethylated DNA substrates in DMB assays according to Yokochi and Robertson (2004) 22 
